Ann: Dimerix Completes $5.8m Placement, page-2

DIMERIX RAISES $5.8 MILLION TO SUPPORT DMX-200
CLINICAL PROGRAMS FOR ARDS IN PATIENTS WITH
COVID-19 AND KIDNEY DISEASE
Key Highlights
• Dimerix raises A$5.8 million through a strongly supported Placement to Institutions, as well as
new and existing sophisticated and professional investors
• Funds raised will predominantly be used to support activities associated with the global
REMAP-CAP study of DMX-200 in Acute Respiratory Distress Syndrome (ARDS) in patients with
COVID-19, and which are all equally applicable to the renal programs
MELBOURNE, Australia, 22 June 2020: Dimerix Limited (ASX: DXB) (“Dimerix” or the “Company”), a
clinical-stage biopharmaceutical company, is pleased to announce the placement of 16,222,580 fully
paid ordinary shares in the Company to institutional and sophisticated investors at a price of $0.36
per share to raise $5.8 million (before costs) (Placement).
The Placement was well supported with strong participation from Institutions as well as new and
existing sophisticated and professional investors.
This funding will be used to support activities associated with the global REMAP-CAP study of
DMX-200 in ARDS patients with COVID-19 as well as the next stage of development for the renal
program, such as logistics and distribution costs, additional manufacturing scale-up costs, resource
costs, general working capital and corporate costs.
The Shares issued under the Placement will be issued on the same terms, and will rank equally with,
the existing ordinary shares of Dimerix Limited.
Dr James Williams, Chairman of Dimerix commented “This is a very exciting time for Dimerix. With
DMX-200 nearing completion of two different Phase 2 clinical trials, and read-outs expected mid2020; DMX-200 now entering a global, pivotal study protocol in patients with Acute Respiratory
Distress Syndrome as a result of COVID-19; and DMX-700 under-going proof-of-concept studies,
2020 has the potential to be a transformational year for the Company”.
“The REMAP-CAP team running the global study in COVID-19 patients see DMX-200 in this study as
biologically compelling, operationally feasible, and potentially of tremendous clinical impact for a
condition with high morbidity and mortality and for which few effective therapies are available” said
Dimerix CEO & Managing Director Dr Nina Webster. “These funds will provide a solid runway to
pursue the longer term strategy, including the planning for the success of DMX-200 in the kidney
program, as well as the ARDS associated with COVID-19 program”.
About the Placement
The Placement was offered to Institutions as well as sophisticated and professional investors in
Australia at $0.36 per share, representing an 18.2% discount to the last closing price (44 cents) on 17
June 2020 and a 9.4% discount to the 15-day Volume Weighted Average Price (VWAP). The
Placement was managed by Taylor Collison as Lead Manager and Argonaut as Co-Manager.
16,222,580 Placement shares will be issued within the Company’s existing placement capacity under
ASX Listing Rule 7.1.
Settlement and allotment of the Placement shares is expected to take place later this week or during
the week commencing 29 June 2020 as appropriate, with the shares admitted to trading shortly
thereafter.
For further information, please visit our website at www.dimerix.com or contact:
Dr Nina Webster, Dimerix Limited
Chief Executive Officer & Managing Director
Tel: +61 1300 813 321
E: [email protected]
Rudi Michelson
Monsoon Communications
Tel: +61 3 9620 3333
Mob: +61 (0)411 402 737
E: [email protected]
Authorised for lodgement by the Board of the Company